Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 6, 2026 | $0.23 | −81.3% | $989.71M | +19.9% | $0.94 |
| Q1 FY26ended Mar 31, 2026 | May 7, 2026 | $0.54 | −43.2% | $766.21M | +2.8% | $1.00 |
| Q4 FY25ended Dec 31, 2025 | — | −$0.23 | −134.8% | $874.57M | +17.0% | — |
| Q3 FY25ended Sep 30, 2025 | — | −$0.16 | −129.1% | $776.13M | +4.1% | — |
| Q2 FY25ended Jun 30, 2025 | — | $1.23 | +123.6% | $825.41M | +15.9% | — |
| Q1 FY25ended Mar 31, 2025 | — | $0.95 | +106.5% | $745.15M | +14.8% | — |
| Q4 FY24ended Dec 31, 2024 | — | $0.66 | +500.0% | $747.31M | +15.6% | — |
| Q3 FY24ended Sep 30, 2024 | — | $0.55 | +161.9% | $745.74M |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe BioMarin Pharmaceutical shares, not any token. As of Aug 6, 2026, from Massive's standardised financials and the earnings calendar.
| +28.3% |
| — |
| Q2 FY24ended Jun 30, 2024 | — | $0.55 | — | $712.03M | — | — |
| Q1 FY24ended Mar 31, 2024 | — | $0.46 | — | $648.83M | — | — |
| Q4 FY23ended Dec 31, 2023 | — | $0.11 | — | $646.21M | — | — |
| Q3 FY23ended Sep 30, 2023 | — | $0.21 | — | $581.33M | — | — |